JP2023542523A5 - - Google Patents
Info
- Publication number
- JP2023542523A5 JP2023542523A5 JP2023518177A JP2023518177A JP2023542523A5 JP 2023542523 A5 JP2023542523 A5 JP 2023542523A5 JP 2023518177 A JP2023518177 A JP 2023518177A JP 2023518177 A JP2023518177 A JP 2023518177A JP 2023542523 A5 JP2023542523 A5 JP 2023542523A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063082162P | 2020-09-23 | 2020-09-23 | |
| US63/082,162 | 2020-09-23 | ||
| US202063084900P | 2020-09-29 | 2020-09-29 | |
| US63/084,900 | 2020-09-29 | ||
| PCT/IB2021/058662 WO2022064399A1 (en) | 2020-09-23 | 2021-09-22 | Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023542523A JP2023542523A (ja) | 2023-10-10 |
| JP2023542523A5 true JP2023542523A5 (https=) | 2024-10-04 |
| JPWO2022064399A5 JPWO2022064399A5 (https=) | 2024-10-04 |
Family
ID=80845024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023518177A Pending JP2023542523A (ja) | 2020-09-23 | 2021-09-22 | 抗ｃｄ７３及び抗ｐｄ－ｌ１抗体並びに化学療法を使用する治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240010746A1 (https=) |
| EP (1) | EP4217072A4 (https=) |
| JP (1) | JP2023542523A (https=) |
| KR (1) | KR20230074206A (https=) |
| CN (1) | CN116209468A (https=) |
| AU (1) | AU2021349415A1 (https=) |
| BR (1) | BR112023004594A2 (https=) |
| CA (1) | CA3194926A1 (https=) |
| IL (1) | IL301376A (https=) |
| WO (1) | WO2022064399A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4626552A1 (en) * | 2022-12-01 | 2025-10-08 | MedImmune Limited | Combination therapy for treatment of cancer comprising anti-pd-l1 and anti-cd73 antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230038311A (ko) * | 2016-03-04 | 2023-03-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd73 항체와의 조합 요법 |
| CN118307674A (zh) * | 2017-06-22 | 2024-07-09 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| TWI823906B (zh) * | 2018-03-09 | 2023-12-01 | 美商艾吉納斯公司 | 抗-cd73 抗體及其使用方法 |
| US20200317803A1 (en) * | 2019-04-02 | 2020-10-08 | Medimmune, Llc | Anti-cd73, anti-pd-l1 antibodies and chemotherapy for treating tumors |
-
2021
- 2021-09-22 CN CN202180063881.XA patent/CN116209468A/zh active Pending
- 2021-09-22 US US18/246,206 patent/US20240010746A1/en active Pending
- 2021-09-22 CA CA3194926A patent/CA3194926A1/en active Pending
- 2021-09-22 EP EP21871791.6A patent/EP4217072A4/en not_active Withdrawn
- 2021-09-22 WO PCT/IB2021/058662 patent/WO2022064399A1/en not_active Ceased
- 2021-09-22 JP JP2023518177A patent/JP2023542523A/ja active Pending
- 2021-09-22 AU AU2021349415A patent/AU2021349415A1/en not_active Abandoned
- 2021-09-22 IL IL301376A patent/IL301376A/en unknown
- 2021-09-22 KR KR1020237013299A patent/KR20230074206A/ko active Pending
- 2021-09-22 BR BR112023004594A patent/BR112023004594A2/pt unknown